SCHEMBL4130945

SCHEMBL4130945

c1cc(N2CCC3(CC2)CCN(C2CCC2)CC3)ncc1N1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 13/20 0.43
L3MBTL3 Q96JM7 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
UBE2T Q9NPD8 1/20 0.40
DGAT1 O75907 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MBTD1 Q05BQ5 1/20 0.37
HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938014 0.99 HRH3 (0.42) HRH3L3MBTL3L3MBTL1UBE2TDGAT1
SCHEMBL4136714 0.95 L3MBTL3 (0.51) HRH3L3MBTL3L3MBTL1MBTD1
SCHEMBL4289427 0.94 L3MBTL3 (0.50) HRH3L3MBTL3L3MBTL1MBTD1
SCHEMBL4147059 0.94 HRH3 (0.45) HRH3DGAT1HSD11B1
SCHEMBL4934963 0.90 HRH4 (0.41) HRH3DGAT1MAPTKDM4EMEN1
SCHEMBL4137300 0.90 HRH3 (0.53) HRH3L3MBTL3L3MBTL1DGAT1MEN1
SCHEMBL4139795 0.90 ALDH1A1 (0.51) HRH3L3MBTL3L3MBTL1MAPTKDM4E
SCHEMBL4131366 0.90 MAPT (0.43) HRH3L3MBTL3L3MBTL1DGAT1MAPT
SCHEMBL4938890 0.89 HRH3 (0.47) HRH3L3MBTL3L3MBTL1DGAT1MAPT
SCHEMBL4428129 0.88 SMN1; SMN2 (0.46) HRH3L3MBTL3L3MBTL1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 HRH3 1/4885L3MBTL3 2655/4885L3MBTL1 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.